+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tantalizing Therapeutics in Bronchopulmonary Dysplasia

  • ID: 4894803
  • Book
  • June 2020
  • 288 Pages
  • Elsevier Science and Technology
1 of 3

Tantalizing Therapeutics in Bronchopulmonary Dysplasia is a concise reference that provides an overview of emerging concepts in the understanding of lung development and injury from a molecular and cellular point-of-view, including exciting pathways that are paving the way for new options to prevent or treat Bronchopulmonary Dysplasia (BPD). The book's chapters are written by experts who are at the forefront of BPD research. Coverage includes chapters on exosomes, stem cells and miRs, as well as a section on new discoveries in BPD research with translational potential. This is a must-have reference for researchers, physicians and trainees working on BPD, lung developmental biology, and more.

  • Includes discussions on which aspects of the bench research in Bronchopulmonary Dysplasia are the most promising areas
  • Offers insights into the latest research being conducted that could potentially move to the bassinet (in the NICU)
  • Contains evidence-based summaries and informed opinions about existing therapies

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3
Section 1: Current Therapeutics: State of the Art

1. Systemic and topical glucocorticoids to prevent BPD

Kristi Watterberg and Olivier Baud

2. Use of caffeine for prevention of BPD

Abhay Lodha, Stefani Doucette, and Vineet Bhandari

3. Next Generation ventilator strategies to prevent/manage BPD

Martin Keszler and Ashish Gupta

Section 2: Ongoing Therapeutic Studies with Translational Potential

4. End points for therapeutic trials for BPD: lessons learned from clinical trials

Judy L. Aschner and Cynthia T. McEvoy

5. What can exogenous surfactant provide in the fight against BPD?

Peter A. Dargaville

6. Stem cells in the treatment of BPD

So Yoon Ahn, Yun Sil Chang, Won Soon Park

Section 3: Future Therapeutic Directions

7. Extracellular vesicles in the therapy of BPD

Flore Lesage and Bernard Thebaud

8. Growth factors in the therapy of BPD

Heber C. Nielsen, Anne Chetty, and Vineet Bhandari

9. Antenatal approaches in the therapy of BPD

Andre Gie, Ignacio Valenzuela, Thomas Salaets, Jan Deprest, and Jaan Toelen

10. miRs -mere hype or master regulators in the therapy of BPD?

Charitharth Vivek Lal, Vivek Shukla, Namasivayam Ambalavanan, and Vineet Bhandari

11. Immune modulators for the therapy of BPD

Margaret Gilfillan and Vineet Bhandari
Note: Product cover images may vary from those shown
3 of 3
Bhandari, Vineet
Dr. Bhandari is the Division Head of Neonatology at The Children's Regional Hospital at Cooper/Cooper Medical School of Rowan University, Camden, NJ. He previously served as a Professor in the Department of Pediatrics at Drexel University College of Medicine, Philadelphia, PA and an Associate Professor of Pediatrics and Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine, New Haven, CT. Dr. Bhandari has been awarded three patents, with a fourth pending. He is an Associate Editor of Pediatric Research, BMC Pediatrics, Frontiers in Pediatrics and Internet Journal of Medical Update. He is on the editorial board of Journal of Perinatology. He has also served as Guest Editor, Managing Editor and Contributing Editor of several other publications. He is a manuscript reviewer for almost 100 research publications and has published over 290 peer-reviewed articles and chapters in books.
Note: Product cover images may vary from those shown
Adroll
adroll